Compare Las Vegas Sands Corp. (LVS) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Las Vegas Sands Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? Las Vegas Sands Corp. trades at $45.5 (market cap $30.36B), while Vertex Pharmaceuticals Incorporated trades at $478.11 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4× Las Vegas Sands Corp.'s market cap, and Las Vegas Sands Corp. pays a 2.4% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| LVS | VRTX | |
|---|---|---|
Market Cap | $30.36B | $121.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $69.49 | $529.59 |
52-Week Low | $44.78 | $366.54 |
Enterprise Value | $42.75B | $116.69B |
Dividend Yield | 2.4% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LVS trades at $45.47, showing modest 0.24% daily gains amid bearish technical signals. The company demonstrates strong fundamental performance with consistent earnings beats, including Q1 2026 EPS of $0.91 exceeding expectations by 20%. Revenue growth accelerated to $13.02B in 2025, while maintaining solid profitability with 13.41% net margins. Recent corporate actions include a $0.30 dividend payment and $740M share repurchases in Q1 2026.
Analyst consensus remains strongly bullish with 61% buy ratings and $64.75 price target representing 42% upside. Key risks include high debt levels at 73.15% debt-to-asset ratio and potential regulatory headwinds in gaming markets. The combination of strong earnings momentum, attractive valuation at 16.9 P/E, and positive institutional sentiment supports a constructive outlook despite near-term technical weakness.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
